Publications by authors named "N Younan"
Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens.
Methods: The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3.
Introduction: Atrial fibrillation (AF) is the most common arrhythmia and confers an increased risk of mortality, stroke, heart failure and cognitive decline. There is growing interest in AF screening; however, the most suitable population and device for AF detection remains to be elucidated. Here, we present the design of the CONSIDERING-AF (deteCtiON and Stroke preventIon by moDEl scRreenING for Atrial Fibrillation) study.
View Article and Find Full Text PDFBackground: Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Methods: We retrospectively reviewed the medical and radiological files of patients with 1p/19q codeleted, IDH-mutant anaplastic oligodendrogliomas treated with PCV chemotherapy alone who presented magnetic resonance imaging (MRI) modifications suggestive of tumour progression and in whom the final diagnosis was a pseudoprogression.
Article Synopsis
- - Most relapses of primary central nervous system lymphoma (PCNSL) typically occur in the brain and have a poor prognosis, while isolated intraocular relapses (IIORs) are rare and not well understood.
- - A study analyzed 55 PCNSL patients with IIOR and found that a significant number had high IL-10 levels in their eye fluid, and the majority received systemic chemotherapy, with some undergoing high-dose chemotherapy followed by stem cell transplantation (HCT-ASCT).
- - After an average follow-up of nearly 6 years, 76% of patients relapsed, especially those who didn't have HCT-ASCT; however, prognosis was better for IIOR compared to brain relapses, undersc
Article Synopsis
- * The evaluation included 88 patients, with 51.1% using a molecularly-oriented approach, showing a higher rate of stable disease and positive response among them (25.7%) compared to non-molecularly-oriented patients (5.1%).
- * Results indicate that molecular profiling could improve outcomes for certain glioma patients, highlighting the need for larger studies to validate these findings and pinpoint ideal candidates for this strategy.